Trial Profile
Effects of alisertib (MLN8237), an investigational Aurora A kinase inhibitor (AAKi), on the QTc interval in patients (pts) with advanced malignancies
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2016
Price :
$35
*
At a glance
- Drugs Alisertib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 01 Feb 2016 New trial record